Ed Arce
Stock Analyst at WestPark Capital
(4.22)
# 455
Out of 5,124 analysts
406
Total ratings
45.88%
Success rate
17.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $24 → $28 | $15.77 | +77.55% | 13 | Sep 30, 2025 | |
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $38.21 | -21.49% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $132 | $8.42 | +1,467.70% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $5.77 | +1,199.83% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $6.13 | +878.79% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $1.61 | +365.84% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $4.65 | +179.57% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $4.16 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $1.14 | +426.32% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $9.32 | +651.07% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $34.01 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $2.49 | +9,538.55% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.22 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $5.92 | +440.54% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $35 | $220.89 | -84.16% | 22 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $78.99 | -8.85% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $582.34 | -30.45% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $5.83 | -5.66% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $23.00 | +313.04% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $4.81 | +3.95% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $35.08 | +36.83% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $40.40 | -81.44% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.34 | +1,392.54% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $15.95 | -18.50% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.12 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $50.64 | -50.63% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.75 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $17.49 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $35.18 | -80.10% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $46.30 | -54.64% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.57 | - | 2 | Feb 15, 2017 |
Enanta Pharmaceuticals
Sep 30, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $15.77
Upside: +77.55%
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $38.21
Upside: -21.49%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $132
Current: $8.42
Upside: +1,467.70%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $5.77
Upside: +1,199.83%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $6.13
Upside: +878.79%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $1.61
Upside: +365.84%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $4.65
Upside: +179.57%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $4.16
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $1.14
Upside: +426.32%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $9.32
Upside: +651.07%
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $34.01
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $2.49
Upside: +9,538.55%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.22
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $5.92
Upside: +440.54%
Mar 10, 2025
Maintains: Buy
Price Target: $24 → $35
Current: $220.89
Upside: -84.16%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $78.99
Upside: -8.85%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $582.34
Upside: -30.45%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $5.83
Upside: -5.66%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $23.00
Upside: +313.04%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $4.81
Upside: +3.95%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $35.08
Upside: +36.83%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $40.40
Upside: -81.44%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $0.34
Upside: +1,392.54%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $15.95
Upside: -18.50%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.12
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $50.64
Upside: -50.63%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.75
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $17.49
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $35.18
Upside: -80.10%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $46.30
Upside: -54.64%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.57
Upside: -